Banner

Santen Pharmaceuticals ends phaco device development

Article

Phacor Inc., the California-based wholly owned subsidiary of Santen Pharmaceuticals Co. Ltd., ceased operations after 6 years of phacoemulsification system development.

Related Videos
Related Content

FDA grants 510(k) clearance to Altris IMS platform

October 4th 2023

Eyepod: Ocugen CEO gives update on OCU400

October 2nd 2023

Treating dry eye and other ocular conditions may take a village

October 3rd 2023

EyePod: Week in Review - September 24, 2023

September 30th 2023

Dopavision completes enrollment in trial for the digital treatment of myopia

October 2nd 2023

Imaging outlines half-dose vs full-dose ultrawidefield fluorescein angiography

October 2nd 2023

FDA grants 510(k) clearance to Altris IMS platform

October 4th 2023

Eyepod: Ocugen CEO gives update on OCU400

October 2nd 2023

Treating dry eye and other ocular conditions may take a village

October 3rd 2023

EyePod: Week in Review - September 24, 2023

September 30th 2023

Dopavision completes enrollment in trial for the digital treatment of myopia

October 2nd 2023

Imaging outlines half-dose vs full-dose ultrawidefield fluorescein angiography

October 2nd 2023

FDA grants 510(k) clearance to Altris IMS platform

October 4th 2023

Eyepod: Ocugen CEO gives update on OCU400

October 2nd 2023

Treating dry eye and other ocular conditions may take a village

October 3rd 2023

EyePod: Week in Review - September 24, 2023

September 30th 2023

Dopavision completes enrollment in trial for the digital treatment of myopia

October 2nd 2023

Imaging outlines half-dose vs full-dose ultrawidefield fluorescein angiography

October 2nd 2023
© 2023 MJH Life Sciences

All rights reserved.